Your email has been successfully added to our mailing list.

×
0 0 -0.00230680507497112 -0.00346020761245667 -0.00922722029988467 -0.0426758938869665 -0.0431603229527105 -0.0830449826989619
Stock impact report

Viking launches mid-stage study of VK2809 in NASH; shares up 7% premarket [Seeking Alpha]

Viking Therapeutics, Inc. (VKTX) 
Last viking therapeutics, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vikingtherapeutics.com
Company Research Source: Seeking Alpha
Viking launches mid-stage study of VK2809 in NASH; shares up 7% premarket Viking Therapeutics (NASDAQ: VKTX 7% announcement The primary endpoint of the 340-subject study is the relative change in liver fat content from baseline to week 12 as measured by magnetic resonance imaging, proton density fat fraction (MRI-PDFF). Related ticker: Madrigal Pharmaceuticals (NASDAQ: MDGL Show less Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for VKTX alerts
Opt-in for
VKTX alerts

from News Quantified
Opt-in for
VKTX alerts

from News Quantified